慢性鼻竇炎伴隨鼻息肉市場:各治療類型，各給藥途徑，各流通管道，各地區，機會，預測，2017年～2031年

2024-2031年預測期間，全球慢性鼻竇炎伴隨鼻息肉市場規模將以6.95%的複合年增長率擴大，從2023年的35.4億美元增至2031年的62.46億美元。 10.95億美元。

慢性鼻竇炎伴隨鼻息肉（CRSwNP）是一種以鼻竇持續發炎和存在稱為鼻息肉的良性發炎病變為特徵的疾病。鼻息肉通常發生在篩竇，可阻塞鼻腔氣道，導致臉部壓力和疼痛、鼻塞、嗅覺減退或嗅覺喪失（嗅覺減少或完全消失），鼻涕會引起各種症狀。

由於人口老化、空氣污染、過度吸菸等諸多原因，慢性鼻竇炎的盛行率正在上升，並且預計將繼續上升，市場預計將因此增長。針對特定發炎途徑治療與鼻息肉相關的慢性鼻竇炎的生物製劑的開發和監管批准正在顯著推動市場成長。由於人們對該疾病及其治療方法的認識不斷增強，預計該市場將會成長。特別是 TEZSPIRE (tezepelumab) 和 Depemokimab/GSK3511294 等新藥預計將推動市場發展。

2023年3月，OptiNose US, Inc.宣布XHANCE的補充新藥申請（sNDA）被美國FDA接受。 XHANCE 利用呼氣輸送系統 (EDS) 將丙酸氟替卡松（一種廣泛使用的鼻腔抗炎藥）輸送到難以進入的鼻竇和鼻竇引流通道。 sNDA 備案是根據 ReOpen 計劃中兩項 3 期臨床試驗的結果，該計劃研究了慢性鼻竇炎的治療。

本報告提供全球慢性鼻竇炎伴隨鼻息肉市場相關調查，提供市場概要，以及各治療類型，各給藥途徑，各流通管道，各地區趨勢，及加入此市場的主要企業簡介等資訊。

目錄

第1章 計劃的範圍和定義

第2章 調查手法

第3章 摘要整理

第4章 全球慢性鼻竇炎伴隨鼻息肉的市場預測，2017年～2031年

• 市場規模的分析與預測
• 市場佔有率分析與預測
• 市場地圖分析，2023年
  • 各治療類型
  • 各給藥途徑
  • 各流通管道
  • 各地區

第5章 北美的慢性鼻竇炎伴隨鼻息肉的市場預測，2017年～2031年

第6章 歐洲的慢性鼻竇炎伴隨鼻息肉的市場預測，2017年～2031年

第7章 亞太地區的慢性鼻竇炎伴隨鼻息肉的市場預測，2017年～2031年

第8章 南美的慢性鼻竇炎伴隨鼻息肉的市場預測，2017年～2031年

第9章 中東·非洲的慢性鼻竇炎伴隨鼻息肉的市場預測，2017年～2031年

第10章 生物醫藥品市場- 數量資料，2023年及2031年預測

第11章 需求供給分析

第12章 價值鏈分析

第13章 大環境分析

第14章 波特的五力分析

第15章 市場動態

第16章 市場趨勢與發展

第17章 政策和法規情形

第18章 價格分析

第19章 專利的形勢

第20章 案例研究

第21章 競爭情形

• 前五名市場領導的競爭矩陣
• 前五名參與企業的SWOT分析
• 前10名市場參與企業的形勢
  • Sanofi-Aventis US LLC
  • GlaxoSmithKline plc
  • Genentech, Inc.
  • Novartis Pharmaceuticals Corporation
  • Regeneron Pharmaceuticals Inc.
  • AstraZeneca plc
  • Intersect ENT Inc.
  • Keymed Biosciences Inc.
  • OptiNose US, Inc.
  • Chongqing Genrix Biopharmaceutical Co., Ltd.

第22章 策略性建議

第23章 諮詢方式和免責聲明

Global chronic rhinosinusitis with nasal polyps market is projected to witness a CAGR of 6.95% during the forecast period 2024-2031, growing from USD 3,540.00 million in 2023 to USD 6246.16 million by 2031.

Chronic rhinosinusitis with nasal polyps (CRSwNP) is a condition characterized by persistent inflammation of the sinuses and the presence of benign inflammatory lesions called nasal polyps. These polyps typically develop in the ethmoid sinuses and can obstruct the nasal airways, leading to various symptoms such as facial pressure or pain, nasal congestion, hyposmia or anosmia (reduced or complete lack of smell), and postnasal drip.

The market is anticipated to grow under the influence of the growing prevalence of chronic rhinosinusitis, which is anticipated to keep rising due to the increasing geriatric population, air pollution, excessive smoking, and many other reasons. The development of biologic therapies targeting specific inflammatory pathways for treating chronic rhinosinusitis with nasal polyps and their regulatory approvals have significantly enhanced the market's growth. The market is expected to grow due to the increasing awareness about disease and its available treatments. The market is expected to be driven by emerging drugs such as TEZSPIRE (tezepelumab) and Depemokimab/GSK3511294, among other factors. The development and manufacturing of me of the major factors hampering the growth of the market.

In March 2023, OptiNose US, Inc. announced that its supplemental new drug application (sNDA) for XHANCE has been accepted for review by the US FDA. XHANCE is a drug-device combination product that utilizes the Exhalation Delivery System (EDS) to deliver fluticasone propionate, a widely used nasal anti-inflammatory drug, high and deep into difficult-to-access sinuses and sinonasal drainage tracts. The sNDA submission is based on the results of two phase 3 clinical trials from the ReOpen Program, which studied the treatment of chronic sinusitis.

Growing Prevalence of Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)

The prevalence of CRSwNP is consistently increasing. The disease burden is particularly high in patients with comorbid asthma and/or nonsteroidal anti-inflammatory drug-exacerbated respiratory disease (NSAID-ERD) and in patients who need repeated treatment with systemic corticosteroids and/or surgery. Symptoms in CRSwNP patients include rhinorrhea, nasal congestion, and loss of smell. These symptoms impair physical and mental health, including sleep quality. Targeted treatment of nasal polyps and the underlying processes of chronic sinus inflammation are medically necessary. Novel, well-tolerated therapies that provide effective symptom control minimize recurrence rates of nasal polyps, which are being promoted and marketed by key players to cater to the requirements.

According to an article published in 'Allergy, Asthma & Clinical Immunology' journal in December 2023, chronic rhinosinusitis is estimated to affect about 2 to 14% of the United States population, out of which about 25 to 30% of cases are associated with the presence of nasal polyps (CRSwNP).

Clinical Developments for Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)

Chronic rhinosinusitis with nasal polyps (CRSwNP) is usually associated with asthma and allergic rhinitis. Diagnosis of CRSwNP is done by bilateral endoscopic visualization of polyps in the nasal area. Treatment options for CRSwNP include topical irrigation and intranasal corticosteroids, systemic corticosteroids, monoclonal antibodies, surgery, and biological therapies targeting underlying inflammatory processes. Additionally, targeting the underlying inflammatory pathways involved in the pathophysiology of CRSwNP and offering new treatment options for patients with more severe or unresponsive diseases have been significant milestones for the treatment of CRSwNP. The role of biologics and corticosteroids in the market and advancements in these drug categories are anticipated to drive growth in the market. Various promising products in the clinical pipeline seem to contribute to the market expansion.

For instance, GSK's Depemokimab (GSK3511294) is a pipeline drug that is expected to complete phase III clinical trials in the third quarter of the year 2024 and has shown significant efficacy in phase I and II clinical trials. Similarly, in January 2024, Upstream Bio announced the entry of a phase II clinical trial and the beginning of dosing the first patients with Verekitug (UPB-101) for the treatment of chronic rhinosinusitis with nasal polyps (CRSwNP).

Biologics Segment Holds Dominance in Chronic Rhinosinusitis with Nasal Polyps Market

The biologics segment leads the chronic rhinosinusitis with nasal polyps (CRSwNP) market, as it promotes one of the most directed forms of treatment available. Biologics precisely modulates specific inflammatory pathways that drive the disease, resulting in significant symptom relief and fewer interventions through surgery. In chronic cases, biologics are predominantly beneficial for patients who cannot respond to conventional therapies. The high efficacy and safety of biologics make them a preferred option among healthcare providers, thus fueling their adoption. Consequently, the growing success of this targeted therapy underpins its market dominance in managing CRSwNP symptoms and improving patient outcomes.

For instance, in April 2023, Nucala became the first monoclonal antibody to be PBS-subsidized by the Australian government to treat CRSwNP. Nucala is the product of GSK plc marketed since 2015. The Australian government's initiative is anticipated to provide subsidized access to this new treatment option for CRSwNP patients.

Parenteral Route of Administration to be the Leading Segment

The predominance of parenteral administration of biologics in the treatment of chronic rhinosinusitis with nasal polyps is mainly because of its efficacy in delivering those drugs that exert their action instantaneously and have a high bioavailability. Biologics, such as dupilumab and mepolizumab, specifically target pathways of the inflammatory processes associated with CRSwNP, and optimum dosing can only be accomplished through parenteral administration. This route bypasses gastrointestinal absorption issues, so drug levels reach systemic circulation quickly and effectively, critical in managing acute symptoms and controlling inflammation in these patients. Additionally, many of the patients with CRSwNP may have gastrointestinal side effects that make oral delivery less feasible.

For instance, in January 2024, Regeneron Pharmaceuticals, Inc. and Sanofi announced that the US Food and Drug Administration approved Dupixent (dupilumab) for the treatment of pediatric patients aged 1 to 11 years and weight of at least 15 kg suffering from eosinophilic esophagitis (EoE). Dupixent became the first medication approved in the United States specifically to treat these patients. The approval expands the approved indication of Dupixent, including atopic dermatitis, chronic rhinosinusitis with nasal polyposis, prurigo nodularis, asthma, and EoE.

North America to Hold the Dominating Share in the Global Market

North America is anticipated to be the leading region in the market with a higher value share. The prevalence of chronic rhinosinusitis with nasal polyps (CRSwNP) in the United States is estimated to be around 2-14% as per various studies. The prevalence of CRSwNP is greater in men than in women. Asthma, allergy, and allergic rhinitis are the most common comorbidities associated with CRSwNP, and the high occurrence of these conditions in North America increases the risk of CRSwNP. Obesity is one of the major risk factors for CRSwNP, and more than 40% of the United States population is obese, further increasing the risk of CRSwNp. Additionally, the strong presence of key market players in the region and the strong clinical pipeline for the treatment option for CRSwNP strengthens North America's lead position. Regulatory emphasis on reducing the disease burden of CRSwNP is expected to expand the market.

For instance, in June 2023, the US Food and Drug Administration made its final industry guidelines titled "Developing Drugs for Treatment of Chronic Rhinosinusitis with Nasal Polyps" public. The guideline is intended to support sponsors in the creation of pharmaceuticals or biological products intended to treat nasal polyps and chronic rhinosinusitis (CRSwNP).

Future Market Scenario (2024-2031F)

The major factor driving the future market scenario is the growing prevalence of chronic rhinosinusitis due to the rising aging population, pollution levels, and smoking tendencies of individuals. Aging and other comorbidities like asthma significantly increase the risk of disease occurrence.

The development of medications for CRSwNP by exploring alternative inflammatory pathways such as interleukins 4, 5, 13, 33, ILC2 cells, and IgE along with other pathogenic mechanisms involved in CRS pathogenesis such as arachidonic acid pathway, extravascular fibrin deposition (coagulation cascade), and B-cell dysregulation, can open the market with newer and more effective drug candidates. For instance, Benralizumab is a promising drug candidate for AstraZeneca undergoing phase III clinical investigations, which are expected to be completed in the early months of 2025.

Key Players Landscape and Outlook

Market players like Sanofi-Aventis US LLC, Regeneron Pharmaceuticals Inc., and GlaxoSmithKline (GSK) plc have several promising products in the clinical pipeline, which shows their market readiness. The regulatory approvals and expansion in approved indications for biologics are anticipated to divert the attention of key players for the development of further biologics and biosimilar products in the forecast years.

In January 2024, GSK plc completed the acquisition of Aiolos Bio, Inc., a clinical-stage biopharmaceutical company focused on the unmet treatment needs of patients with specific respiratory and inflammatory conditions. The deal was valued at USD 1.4 billion. The acquisition enables GSK with access to Aiolos' AIO-001, which is a long-acting anti-thymic stromal lymphopoietin monoclonal antibody prepared to enter phase 2 clinical trials for the treatment of adult asthma patients, with the potential for additional indications, including chronic rhinosinusitis with nasal polyps.

Table of Contents

1. Project Scope and Definitions

2. Research Methodology

3. Executive Summary

4. Global Chronic Rhinosinusitis with Nasal Polyps Market Outlook, 2017-2031F

• 4.1. Market Size Analysis & Forecast
  • 4.1.1. By Value
• 4.2. Market Share Analysis & Forecast
  • 4.2.1. By Treatment Type
    • 4.2.1.1. Biologics
      • 4.2.1.1.1. Dupilumab (Dupixent)
      • 4.2.1.1.2. Omalizumab (Xolair)
      • 4.2.1.1.3. Mepolizumab (Nucala)
    • 4.2.1.2. Corticosteroids
    • 4.2.1.3. Antibiotics
    • 4.2.1.4. Antifungal Drugs
    • 4.2.1.5. Others
  • 4.2.2. By Route of Administration
    • 4.2.2.1. Parenteral
    • 4.2.2.2. Oral
    • 4.2.2.3. Nasal
  • 4.2.3. By Distribution Channel
    • 4.2.3.1. Hospital Pharmacies
    • 4.2.3.2. Retail Pharmacies
    • 4.2.3.3. Online Pharmacies
  • 4.2.4. By Region
    • 4.2.4.1. North America
    • 4.2.4.2. Europe
    • 4.2.4.3. Asia-Pacific
    • 4.2.4.4. South America
    • 4.2.4.5. Middle East and Africa
  • 4.2.5. By Company Market Share Analysis (Top 5 Companies and Others - By Value, 2023)
• 4.3. Market Map Analysis, 2023
  • 4.3.1. By Treatment Type
  • 4.3.2. By Route of Administration
  • 4.3.3. By Distribution Channel
  • 4.3.4. By Region

5. North America Chronic Rhinosinusitis with Nasal Polyps Market Outlook, 2017-2031F*

• 5.1. Market Size Analysis & Forecast
  • 5.1.1. By Value
• 5.2. Market Share Analysis & Forecast
  • 5.2.1. By Treatment Type
    • 5.2.1.1. Biologics
      • 5.2.1.1.1. Dupilumab (Dupixent)
      • 5.2.1.1.2. Omalizumab (Xolair)
      • 5.2.1.1.3. Mepolizumab (Nucala)
    • 5.2.1.2. Corticosteroids
    • 5.2.1.3. Antibiotics
    • 5.2.1.4. Antifungal Drugs
    • 5.2.1.5. Others
  • 5.2.2. By Route of Administration
    • 5.2.2.1. Parenteral
    • 5.2.2.2. Oral
    • 5.2.2.3. Nasal
  • 5.2.3. By Distribution Channel
    • 5.2.3.1. Hospital Pharmacies
    • 5.2.3.2. Retail Pharmacies
    • 5.2.3.3. Online Pharmacies
  • 5.2.4. By Country Share
    • 5.2.4.1. United States
    • 5.2.4.2. Canada
    • 5.2.4.3. Mexico
• 5.3. Country Market Assessment
  • 5.3.1. United States Chronic Rhinosinusitis with Nasal Polyps Market Outlook, 2017-2031F*
    • 5.3.1.1. Market Size Analysis & Forecast
      • 5.3.1.1.1. By Value
    • 5.3.1.2. Market Share Analysis & Forecast
      • 5.3.1.2.1. By Treatment Type
        • 5.3.1.2.1.1. Biologics
        • 5.3.1.2.1.1.1. Dupilumab (Dupixent)
        • 5.3.1.2.1.1.2. Omalizumab (Xolair)
        • 5.3.1.2.1.1.3. Mepolizumab (Nucala)
        • 5.3.1.2.1.2. Corticosteroids
        • 5.3.1.2.1.3. Antibiotics
        • 5.3.1.2.1.4. Antifungal Drugs
        • 5.3.1.2.1.5. Others
      • 5.3.1.2.2. By Route of Administration
        • 5.3.1.2.2.1. Parenteral
        • 5.3.1.2.2.2. Oral
        • 5.3.1.2.2.3. Nasal
      • 5.3.1.2.3. By Distribution Channel
        • 5.3.1.2.3.1. Hospital Pharmacies
        • 5.3.1.2.3.2. Retail Pharmacies
        • 5.3.1.2.3.3. Online Pharmacies
  • 5.3.2. Canada
  • 5.3.3. Mexico

All segments will be provided for all regions and countries covered

6. Europe Chronic Rhinosinusitis with Nasal Polyps Market Outlook, 2017-2031F

• 6.1. Germany
• 6.2. France
• 6.3. Italy
• 6.4. United Kingdom
• 6.5. Russia
• 6.6. Netherlands
• 6.7. Spain
• 6.8. Turkey
• 6.9. Poland

7. Asia-Pacific Chronic Rhinosinusitis with Nasal Polyps Market Outlook, 2017-2031F

• 7.1. India
• 7.2. China
• 7.3. Japan
• 7.4. Australia
• 7.5. Vietnam
• 7.6. South Korea
• 7.7. Indonesia
• 7.8. Philippines

8. South America Chronic Rhinosinusitis with Nasal Polyps Market Outlook, 2017-2031F

• 8.1. Brazil
• 8.2. Argentina

9. Middle East and Africa Chronic Rhinosinusitis with Nasal Polyps Market Outlook, 2017-2031F

• 9.1. Saudi Arabia
• 9.2. UAE
• 9.3. South Africa

10. Biologics Market - Volume Data, 2023 and 2031F

11. Demand Supply Analysis

12. Value Chain Analysis

13. PESTLE Analysis

14. Porter's Five Forces Analysis

15. Market Dynamics

• 15.1. Market Drivers
• 15.2. Market Challenges

16. Market Trends and Developments

17. Policy And Regulatory Landscape

• 17.1. Clinical Trials
• 17.2. Regulatory Approvals

18. Pricing Analysis

19. Patent Landscape

20. Case Studies

21. Competitive Landscape

• 21.1. Competition Matrix of Top 5 Market Leaders
• 21.2. SWOT Analysis for Top 5 Players
• 21.3. Key Players Landscape for Top 10 Market Players
  • 21.3.1. Sanofi-Aventis US LLC
    • 21.3.1.1. Company Details
    • 21.3.1.2. Key Management Personnel
    • 21.3.1.3. Products and Services
    • 21.3.1.4. Financials (As Reported)
    • 21.3.1.5. Key Market Focus and Geographical Presence
    • 21.3.1.6. Recent Developments/Collaborations/Partnerships/Mergers and Acquisition
  • 21.3.2. GlaxoSmithKline plc
  • 21.3.3. Genentech, Inc.
  • 21.3.4. Novartis Pharmaceuticals Corporation
  • 21.3.5. Regeneron Pharmaceuticals Inc.
  • 21.3.6. AstraZeneca plc
  • 21.3.7. Intersect ENT Inc.
  • 21.3.8. Keymed Biosciences Inc.
  • 21.3.9. OptiNose US, Inc.
  • 21.3.10. Chongqing Genrix Biopharmaceutical Co., Ltd.

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

22. Strategic Recommendations

23. About Us and Disclaimer

List of Tables

• Table 1. Pricing Analysis of Biologics Targeting Chronic Rhinosinusitis with Nasal Polyps, 2023

List of Figures

• Figure 1. Global Chronic Rhinosinusitis with Nasal Polyps Market Size, By Value (USD Million), 2017-2031F
• Figure 2. Global Chronic Rhinosinusitis with Nasal Polyps Market Share, By Treatment Type, By Value, 2017-2031F
• Figure 3. Global Chronic Rhinosinusitis with Nasal Polyps Market Share, By Treatment Type - Biologics, By Value, 2017-2031F
• Figure 4. Global Chronic Rhinosinusitis with Nasal Polyps Market Share, By Route of Administration, By Value, 2017-2031F
• Figure 5. Global Chronic Rhinosinusitis with Nasal Polyps Market Share, By Distribution Channel, By Value, 2017-2031F
• Figure 6. Global Chronic Rhinosinusitis with Nasal Polyps Market Share, By Country, By Value, 2017-2031F
• Figure 7. Global Chronic Rhinosinusitis with Nasal Polyps Market Share, By Company, By Value, 2023
• Figure 8. Global Chronic Rhinosinusitis with Nasal Polyps Market Map, By Treatment Type, By Value, 2023
• Figure 9. Global Chronic Rhinosinusitis with Nasal Polyps Market Map, By Route of Administration, By Value, 2023
• Figure 10. Global Chronic Rhinosinusitis with Nasal Polyps Market Map, By Route of Administration, By Value, 2023
• Figure 11. Global Chronic Rhinosinusitis with Nasal Polyps Market Map, By Region, By Value, 2023
• Figure 12. North America Chronic Rhinosinusitis with Nasal Polyps Market Size, By Value (USD Million), 2017-2031F
• Figure 13. North America Chronic Rhinosinusitis with Nasal Polyps Market Share, By Treatment Type, By Value, 2017-2031F
• Figure 14. North America Chronic Rhinosinusitis with Nasal Polyps Market Share, By Treatment Type - Biologics, By Value, 2017-2031F
• Figure 15. North America Chronic Rhinosinusitis with Nasal Polyps Market Share, By Route of Administration, By Value, 2017-2031F
• Figure 16. North America Chronic Rhinosinusitis with Nasal Polyps Market Share, By Distribution Channel, By Value, 2017-2031F
• Figure 17. North America Chronic Rhinosinusitis with Nasal Polyps Market Share, By Country, By Value, 2017-2031F
• Figure 18. United States Chronic Rhinosinusitis with Nasal Polyps Market Size, By Value (USD Million), 2017-2031F
• Figure 19. United States Chronic Rhinosinusitis with Nasal Polyps Market Share, By Treatment Type, By Value, 2017-2031F
• Figure 20. United States Chronic Rhinosinusitis with Nasal Polyps Market Share, By Treatment Type - Biologics, By Value, 2017-2031F
• Figure 21. United States Chronic Rhinosinusitis with Nasal Polyps Market Share, By Route of Administration, By Value, 2017-2031F
• Figure 22. United States Chronic Rhinosinusitis with Nasal Polyps Market Share, By Distribution Channel, By Value, 2017-2031F
• Figure 23. Canada Chronic Rhinosinusitis with Nasal Polyps Market Size, By Value (USD Million), 2017-2031F
• Figure 24. Canada Chronic Rhinosinusitis with Nasal Polyps Market Share, By Treatment Type, By Value, 2017-2031F
• Figure 25. Canada Chronic Rhinosinusitis with Nasal Polyps Market Share, By Treatment Type - Biologics, By Value, 2017-2031F
• Figure 26. Canada Chronic Rhinosinusitis with Nasal Polyps Market Share, By Route of Administration, By Value, 2017-2031F
• Figure 27. Canada Chronic Rhinosinusitis with Nasal Polyps Market Share, By Distribution Channel, By Value, 2017-2031F
• Figure 28. Mexico Chronic Rhinosinusitis with Nasal Polyps Market Size, By Value (USD Million), 2017-2031F
• Figure 29. Mexico Chronic Rhinosinusitis with Nasal Polyps Market Share, By Treatment Type, By Value, 2017-2031F
• Figure 30. Mexico Chronic Rhinosinusitis with Nasal Polyps Market Share, By Route of Administration, By Value, 2017-2031F
• Figure 31. Mexico Chronic Rhinosinusitis Nasal Polyps Market Share, By Distribution Channel, By Value, 2017-2031F
• Figure 32. Europe Chronic Rhinosinusitis with Nasal Polyps Market Size, By Value (USD Million), 2017-2031F
• Figure 33. Europe Chronic Rhinosinusitis with Nasal Polyps Market Share, By Treatment Type, By Value, 2017-2031F
• Figure 34. Europe Chronic Rhinosinusitis with Nasal Polyps Market Share, By Treatment Type - Biologics, By Value, 2017-2031F
• Figure 35. Europe Chronic Rhinosinusitis with Nasal Polyps Market Share, By Route of Administration, By Value, 2017-2031F
• Figure 36. Europe Chronic Rhinosinusitis with Nasal Polyps Market Share, By Distribution Channel, By Value, 2017-2031F
• Figure 37. Europe Chronic Rhinosinusitis with Nasal Polyps Market Share, By Country, By Value, 2017-2031F
• Figure 38. Germany Chronic Rhinosinusitis with Nasal Polyps Market Size, By Value (USD Million), 2017-2031F
• Figure 39. Germany Chronic Rhinosinusitis with Nasal Polyps Market Share, By Treatment Type, By Value, 2017-2031F
• Figure 40. Germany Chronic Rhinosinusitis with Nasal Polyps Market Share, By Treatment Type - Biologics, By Value, 2017-2031F
• Figure 41. Germany Chronic Rhinosinusitis with Nasal Polyps Market Share, By Route of Administration, By Value, 2017-2031F
• Figure 42. Germany Chronic Rhinosinusitis with Nasal Polyps Market Share, By Distribution Channel, By Value, 2017-2031F
• Figure 43. France Chronic Rhinosinusitis with Nasal Polyps Market Size, By Value (USD Million), 2017-2031F
• Figure 44. France Chronic Rhinosinusitis with Nasal Polyps Market Share, By Treatment Type, By Value, 2017-2031F
• Figure 45. France Chronic Rhinosinusitis with Nasal Polyps Market Share, By Treatment Type - Biologics, By Value, 2017-2031F
• Figure 46. France Chronic Rhinosinusitis with Nasal Polyps Market Share, By Route of Administration, By Value, 2017-2031F
• Figure 47. France Chronic Rhinosinusitis with Nasal Polyps Market Share, By Distribution Channel, By Value, 2017-2031F
• Figure 48. Italy Chronic Rhinosinusitis with Nasal Polyps Market Size, By Value (USD Million), 2017-2031F
• Figure 49. Italy Chronic Rhinosinusitis with Nasal Polyps Market Share, By Treatment Type, By Value, 2017-2031F
• Figure 50. Italy Chronic Rhinosinusitis with Nasal Polyps Market Share, By Treatment Type - Biologics, By Value, 2017-2031F
• Figure 51. Italy Chronic Rhinosinusitis with Nasal Polyps Market Share, By Route of Administration, By Value, 2017-2031F
• Figure 52. Italy Chronic Rhinosinusitis with Nasal Polyps Market Share, By Distribution Channel, By Value, 2017-2031F
• Figure 53. Spain Chronic Rhinosinusitis with Nasal Polyps Market Size, By Value (USD Million), 2017-2031F
• Figure 54. Spain Chronic Rhinosinusitis with Nasal Polyps Market Share, By Treatment Type, By Value, 2017-2031F
• Figure 55. Spain Chronic Rhinosinusitis with Nasal Polyps Market Share, By Treatment Type - Biologics, By Value, 2017-2031F
• Figure 56. Spain Chronic Rhinosinusitis with Nasal Polyps Market Share, By Route of Administration, By Value, 2017-2031F
• Figure 57. Spain Chronic Rhinosinusitis with Nasal Polyps Market Share, By Distribution Channel, By Value, 2017-2031F
• Figure 58. Netherlands Chronic Rhinosinusitis with Nasal Polyps Market Size, By Value (USD Million), 2017-2031F
• Figure 59. Netherlands Chronic Rhinosinusitis with Nasal Polyps Market Share, By Treatment Type, By Value, 2017-2031F
• Figure 60. Netherlands Chronic Rhinosinusitis with Nasal Polyps Market Share, By Treatment Type - Biologics, By Value, 2017-2031F
• Figure 61. Netherlands Chronic Rhinosinusitis with Nasal Polyps Market Share, By Route of Administration, By Value, 2017-2031F
• Figure 62. Netherlands Chronic Rhinosinusitis with Nasal Polyps Market Share, By Distribution Channel, By Value, 2017-2031F
• Figure 63. Poland Chronic Rhinosinusitis with Nasal Polyps Market Size, By Value (USD Million), 2017-2031F
• Figure 64. Poland Chronic Rhinosinusitis with Nasal Polyps Market Share, By Treatment Type, By Value, 2017-2031F
• Figure 65. Poland Chronic Rhinosinusitis with Nasal Polyps Market Share, By Treatment Type - Biologics, By Value, 2017-2031F
• Figure 66. Poland Chronic Rhinosinusitis with Nasal Polyps Market Share, By Route of Administration, By Value, 2017-2031F
• Figure 67. Poland Chronic Rhinosinusitis with Nasal Polyps Market Share, By Distribution Channel, By Value, 2017-2031F
• Figure 68. United Kingdom Chronic Rhinosinusitis with Nasal Polyps Market Size, By Value (USD Million), 2017-2031F
• Figure 69. United Kingdom Chronic Rhinosinusitis with Nasal Polyps Market Share, By Treatment Type, By Value, 2017-2031F
• Figure 70. United Kingdom Chronic Rhinosinusitis with Nasal Polyps Market Share, By Route of Administration, By Value, 2017-2031F
• Figure 71. United Kingdom Chronic Rhinosinusitis with Nasal Polyps Market Share, By Distribution Channel, By Value, 2017-2031F
• Figure 72. Russia Chronic Rhinosinusitis with Nasal Polyps Market Size, By Value (USD Million), 2017-2031F
• Figure 73. Russia Chronic Rhinosinusitis with Nasal Polyps Market Share, By Treatment Type, By Value, 2017-2031F
• Figure 74. Russia Chronic Rhinosinusitis with Nasal Polyps Market Share, By Route of Administration, By Value, 2017-2031F
• Figure 75. Russia Chronic Rhinosinusitis with Nasal Polyps Market Share, By Distribution Channel, By Value, 2017-2031F
• Figure 76. Turkey Chronic Rhinosinusitis with Nasal Polyps Market Size, By Value (USD Million), 2017-2031F
• Figure 77. Turkey Chronic Rhinosinusitis with Nasal Polyps Market Share, By Treatment Type, By Value, 2017-2031F
• Figure 78. Turkey Chronic Rhinosinusitis with Nasal Polyps Market Share, By Route of Administration, By Value, 2017-2031F
• Figure 79. Turkey Chronic Rhinosinusitis with Nasal Polyps Market Share, By Distribution Channel, By Value, 2017-2031F
• Figure 80. Asia-Pacific Chronic Rhinosinusitis with Nasal Polyps Market Size, By Value (USD Million), 2017-2031F
• Figure 81. Asia-Pacific Chronic Rhinosinusitis with Nasal Polyps Market Share, By Treatment Type, By Value, 2017-2031F
• Figure 82. Asia-Pacific Chronic Rhinosinusitis with Nasal Polyps Market Share, By Treatment Type - Biologics, By Value, 2017-2031F
• Figure 83. Asia-Pacific Chronic Rhinosinusitis with Nasal Polyps Market Share, By Route of Administration, By Value, 2017-2031F
• Figure 84. Asia-Pacific Chronic Rhinosinusitis with Nasal Polyps Market Share, By Distribution Channel, By Value, 2017-2031F
• Figure 85. Asia-Pacific Chronic Rhinosinusitis with Nasal Polyps Market Share, By Country, By Value, 2017-2031F
• Figure 86. China Chronic Rhinosinusitis with Nasal Polyps Market Size, By Value (USD Million), 2017-2031F
• Figure 87. China Chronic Rhinosinusitis with Nasal Polyps Market Share, By Treatment Type, By Value, 2017-2031F
• Figure 88. China Chronic Rhinosinusitis with Nasal Polyps Market Share, By Route of Administration, By Value, 2017-2031F
• Figure 89. China Chronic Rhinosinusitis with Nasal Polyps Market Share, By Distribution Channel, By Value, 2017-2031F
• Figure 90. Japan Chronic Rhinosinusitis with Nasal Polyps Market Size, By Value (USD Million), 2017-2031F
• Figure 91. Japan Chronic Rhinosinusitis with Nasal Polyps Market Share, By Treatment Type, By Value, 2017-2031F
• Figure 92. Japan Chronic Rhinosinusitis with Nasal Polyps Market Share, By Treatment Type - Biologics, By Value, 2017-2031F
• Figure 93. Japan Chronic Rhinosinusitis with Nasal Polyps Market Share, By Route of Administration, By Value, 2017-2031F
• Figure 94. Japan Chronic Rhinosinusitis with Nasal Polyps Market Share, By Distribution Channel, By Value, 2017-2031F
• Figure 95. Australia Chronic Rhinosinusitis with Nasal Polyps Market Size, By Value (USD Million), 2017-2031F
• Figure 96. Australia Chronic Rhinosinusitis with Nasal Polyps Market Share, By Treatment Type, By Value, 2017-2031F
• Figure 97. Australia Chronic Rhinosinusitis with Nasal Polyps Market Share, By Treatment Type - Biologics, By Value, 2017-2031F
• Figure 98. Australia Chronic Rhinosinusitis with Nasal Polyps Market Share, By Route of Administration, By Value, 2017-2031F
• Figure 99. Australia Chronic Rhinosinusitis with Nasal Polyps Market Share, By Distribution Channel, By Value, 2017-2031F
• Figure 100. India Chronic Rhinosinusitis with Nasal Polyps Market Size, By Value (USD Million), 2017-2031F
• Figure 101. India Chronic Rhinosinusitis with Nasal Polyps Market Share, By Treatment Type, By Value, 2017-2031F
• Figure 102. India Chronic Rhinosinusitis with Nasal Polyps Market Share, By Route of Administration, By Value, 2017-2031F
• Figure 103. India Chronic Rhinosinusitis with Nasal Polyps Market Share, By Distribution Channel, By Value, 2017-2031F
• Figure 104. South Korea Chronic Rhinosinusitis with Nasal Polyps Market Size, By Value (USD Million), 2017-2031F
• Figure 105. South Korea Chronic Rhinosinusitis with Nasal Polyps Market Share, By Treatment Type, By Value, 2017-2031F
• Figure 106. South Korea Chronic Rhinosinusitis with Nasal Polyps Market Share, By Route of Administration, By Value, 2017-2031F
• Figure 107. South Korea Chronic Rhinosinusitis with Nasal Polyps Market Share, By Distribution Channel, By Value, 2017-2031F
• Figure 108. Vietnam Chronic Rhinosinusitis with Nasal Polyps Market Size, By Value (USD Million), 2017-2031F
• Figure 109. Vietnam Chronic Rhinosinusitis with Nasal Polyps Market Share, By Treatment Type, By Value, 2017-2031F
• Figure 110. Vietnam Chronic Rhinosinusitis with Nasal Polyps Market Share, By Route of Administration, By Value, 2017-2031F
• Figure 111. Vietnam Chronic Rhinosinusitis with Nasal Polyps Market Share, By Distribution Channel, By Value, 2017-2031F
• Figure 112. Indonesia Chronic Rhinosinusitis with Nasal Polyps Market Size, By Value (USD Million), 2017-2031F
• Figure 113. Indonesia Chronic Rhinosinusitis with Nasal Polyps Market Share, By Treatment Type, By Value, 2017-2031F
• Figure 114. Indonesia Chronic Rhinosinusitis with Nasal Polyps Market Share, By Route of Administration, By Value, 2017-2031F
• Figure 115. Indonesia Chronic Rhinosinusitis with Nasal Polyps Market Share, By Distribution Channel, By Value, 2017-2031F
• Figure 116. Philippines Chronic Rhinosinusitis with Nasal Polyps Market Size, By Value (USD Million), 2017-2031F
• Figure 117. Philippines Chronic Rhinosinusitis with Nasal Polyps Market Share, By Treatment Type, By Value, 2017-2031F
• Figure 118. Philippines Chronic Rhinosinusitis with Nasal Polyps Market Share, By Route of Administration, By Value, 2017-2031F
• Figure 119. Philippines Chronic Rhinosinusitis with Nasal Polyps Market Share, By Distribution Channel, By Value, 2017-2031F
• Figure 120. Middle East and Africa Chronic Rhinosinusitis with Nasal Polyps Market Size, By Value (USD Million), 2017-2031F
• Figure 121. Middle East and Africa Chronic Rhinosinusitis with Nasal Polyps Market Share, By Treatment Type, By Value, 2017-2031F
• Figure 122. Middle East and Africa Chronic Rhinosinusitis with Nasal Polyps Market Share, By Route of Administration, By Value, 2017-2031F
• Figure 123. Middle East and Africa Chronic Rhinosinusitis with Nasal Polyps Market Share, By Distribution Channel, By Value, 2017-2031F
• Figure 124. Middle East and Africa Chronic Rhinosinusitis with Nasal Polyps Market Share, By Country, By Value, 2017-2031F
• Figure 125. Saudi Arabia Chronic Rhinosinusitis with Nasal Polyps Market Size, By Value (USD Million), 2017-2031F
• Figure 126. Saudi Arabia Chronic Rhinosinusitis with Nasal Polyps Market Share, By Treatment Type, By Value, 2017-2031F
• Figure 127. Saudi Arabia Chronic Rhinosinusitis with Nasal Polyps Market Share, By Route of Administration, By Value, 2017-2031F
• Figure 128. Saudi Arabia Chronic Rhinosinusitis with Nasal Polyps Market Share, By Distribution Channel, By Value, 2017-2031F
• Figure 129. South Africa Chronic Rhinosinusitis with Nasal Polyps Market Size, By Value (USD Million), 2017-2031F
• Figure 130. South Africa Chronic Rhinosinusitis with Nasal Polyps Market Share, By Treatment Type, By Value, 2017-2031F
• Figure 131. South Africa Chronic Rhinosinusitis with Nasal Polyps Market Share, By Route of Administration, By Value, 2017-2031F
• Figure 132. South Africa Chronic Rhinosinusitis with Nasal Polyps Market Share, By Distribution Channel, By Value, 2017-2031F
• Figure 133. UAE Chronic Rhinosinusitis with Nasal Polyps Market Size, By Value (USD Million), 2017-2031F
• Figure 134. UAE Chronic Rhinosinusitis with Nasal Polyps Market Share, By Treatment Type, By Value, 2017-2031F
• Figure 135. UAE Chronic Rhinosinusitis with Nasal Polyps Market Share, By Route of Administration, By Value, 2017-2031F
• Figure 136. UAE Chronic Rhinosinusitis with Nasal Polyps Market Share, By Distribution Channel, By Value, 2017-2031F
• Figure 137. South America Chronic Rhinosinusitis with Nasal Polyps Market Size, By Value (USD Million), 2017-2031F
• Figure 138. South America Chronic Rhinosinusitis with Nasal Polyps Market Share, By Treatment Type, By Value, 2017-2031F
• Figure 139. South America Chronic Rhinosinusitis with Nasal Polyps Market Share, By Route of Administration, By Value, 2017-2031F
• Figure 140. South America Chronic Rhinosinusitis with Nasal Polyps Market Share, By Distribution Channel, By Value, 2017-2031F
• Figure 141. South America Chronic Rhinosinusitis with Nasal Polyps Market Share, By Country, By Value, 2017-2031F
• Figure 142. Brazil Chronic Rhinosinusitis with Nasal Polyps Market Size, By Value (USD Million), 2017-2031F
• Figure 143. Brazil Chronic Rhinosinusitis with Nasal Polyps Market Share, By Treatment Type, By Value, 2017-2031F
• Figure 144. Brazil Chronic Rhinosinusitis with Nasal Polyps Market Share, By Route of Administration, By Value, 2017-2031F
• Figure 145. Brazil Chronic Rhinosinusitis with Nasal Polyps Market Share, By Distribution Channel, By Value, 2017-2031F
• Figure 146. Argentina Chronic Rhinosinusitis with Nasal Polyps Market Size, By Value (USD Million), 2017-2031F
• Figure 147. Argentina Chronic Rhinosinusitis with Nasal Polyps Market Share, By Treatment Type, By Value, 2017-2031F
• Figure 148. Argentina Chronic Rhinosinusitis with Nasal Polyps Market Share, By Route of Administration, By Value, 2017-2031F
• Figure 149. Argentina Chronic Rhinosinusitis with Nasal Polyps Market Share, By Distribution Channel, By Value, 2017-2031F
• Figure 150. Unit Sales Data for Dupixent, By Major Countries 2023 vs 2031 (Thousand Units)
• Figure 151. Unit Sales Data for Nucala, By Major Countries 2023 vs 2031 (Thousand Units)
• Figure 152. Unit Sales Data for Xolair, By Major Countries 2023 vs 2031 (Thousand Units)
• Figure 153. Top 5 Patent Applicants of Global Chronic Rhinosinusitis with Nasal Polyps Market
• Figure 154. Top 5 Patent Owners of Global Chronic Rhinosinusitis with Nasal Polyps Market
• Figure 155. Total Patents Approved in Last 7 Years in Global Chronic Rhinosinusitis with Nasal Polyps Market